(Q38844384)

6 September 2017

title

Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines (English)

1 reference

6 September 2017

12

1 reference

6 September 2017

Germana Castelli

11

0 references

Elvira Pelosi

object named as

Elvira Pelosi

10

0 references

Francesco Lo Coco

3

object named as

Francesco Lo Coco

1 reference

6 September 2017

0 references

Domenico Mastrangelo

1

1 reference

6 September 2017

Lauretta Massai

2

1 reference

6 September 2017

Nélida Inés Noguera

4

1 reference

6 September 2017

Loredana Borgia

5

1 reference

6 September 2017

Giuseppe Fioritoni

6

1 reference

6 September 2017

Anna Berardi

7

1 reference

6 September 2017

Antonio Iacone

8

1 reference

6 September 2017

Michela Muscettola

9

1 reference

6 September 2017

Francesco Di Pisa

13

1 reference

6 September 2017

Giovanni Grasso

14

1 reference

6 September 2017

publication date

12 August 2015

1 reference

6 September 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Annals of Hematology

1 reference

6 September 2017

volume

94

1 reference

6 September 2017

issue

11

1 reference

6 September 2017

page(s)

1807-1816

1 reference

Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Vitamin C pharmacokinetics: implications for oral and intravenous use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Vitamin C exhibits pro-oxidant properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

The effects of high concentrations of vitamin C on cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

Mitochondrial localization of reactive oxygen species by dihydrofluorescein probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

High concentrations of L-ascorbic acid specifically inhibit the growth of human leukemic cells via downregulation of HIF-1α transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2464-2

10.1007/S00277-015-2464-2

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference